Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Overview
Inhibrx Biosciences Inc (INBX) is a clinical-stage biopharmaceutical company focused on the innovative development of novel biologic therapeutic candidates. Utilizing proprietary modular protein engineering platforms, the company is committed to addressing significant unmet medical needs in oncology and rare diseases through precise, target-centric therapeutic design.
Proprietary Technology and Engineering Excellence
At the heart of Inhibrx Biosciences’ operations is its advanced protein engineering technology. This industry-leading platform enables the development of multivalent formats that allow for precise adjustment of antibody valency. The flexibility of this modular approach provides a tailored agonist function, ensuring each therapeutic candidate is optimized for complex biological targets.
Clinical Pipeline and Therapeutic Candidates
Inhibrx Biosciences has built a robust clinical pipeline featuring a diverse range of novel biologic candidates. These candidates are meticulously engineered using multivalent designs to enhance therapeutic efficacy and safety. The company’s approach is deeply rooted in the application of innovative protein engineering methodologies that help accelerate the path from preclinical research to clinical validation.
Business Model and Market Position
The business model centers on advancing clinical-stage therapeutics using a flexible, data-driven approach. Rather than relying on traditional models, Inhibrx Biosciences emphasizes the use of cutting-edge modular platforms to generate bio-optimized therapeutic candidates. This focus on precision and adaptability not only differentiates the company from its peers but also positions it as a forward-thinking entity in the competitive biopharmaceutical landscape.
Strategic Partnerships and Financial Structuring
Inhibrx Biosciences has secured strategic partnerships and innovative financing solutions to support its clinical programs. Such collaborations provide the company with the necessary capital and operational flexibility to continue its research and development efforts. These partnerships, including tailored term loan facilities from specialized financial institutions, ensure that the company maintains a robust infrastructure for ongoing clinical investigations.
Operational Excellence and Scientific Rigor
The company upholds stringent standards of scientific and operational excellence. Through its proprietary protein engineering techniques and commitment to exhaustive preclinical and clinical evaluations, Inhibrx Biosciences ensures its therapeutic candidates are developed with the highest standards of quality. This rigorous approach reinforces trust and credibility among industry analysts and investors alike.
Expert Insights and Industry Relevance
- Protein Engineering
- Biologic Therapeutics
- Multivalent Formats
By integrating advanced protein engineering with a deep understanding of disease biology, Inhibrx Biosciences continues to innovate in the development of precision-targeted therapies. This expert approach not only augments its clinical pipeline but also contributes to a broader industry narrative of overcoming complex therapeutic challenges in oncology and orphan diseases.
Inhibrx Biosciences (NASDAQ: INBX) announced key leadership changes as co-founder and CSO Dr. Brendan Eckelman departs to establish a new private biotech company. The company has appointed Dr. Carlos Bais, current Executive VP of Translational Sciences, as the new CSO, and promoted David Matly to President while maintaining his existing roles.
As part of the transition, Inhibrx has entered into an exclusive license agreement with Dr. Eckelman's new venture for certain unused technologies, including provisions for upfront payment and future development milestones. David Matly, who played a important role in Inhibrx's $2.2B asset sale of INBRX-101 to Sanofi in 2024, will oversee clinical development, R&D, technical operations, and regulatory affairs in his expanded role.
Inhibrx (Nasdaq: INBX) reported its Q4 and fiscal year 2024 financial results following its spin-off from Former Parent and sale of INBRX-101 to Sanofi in May 2024. The company secured a $100M loan from Oxford Finance in January 2025, with potential for additional $50M funding.
Key clinical developments include promising interim data from ozekibart (INBRX-109) Phase 1 trial in colorectal cancer, showing complete response in one patient, partial responses in three, and stable disease in six patients. The company has initiated a new expansion cohort for up to 50 patients.
Financial highlights:
- Cash position: $230.5M as of February 2025
- Q4 2024: Net loss of $47.9M ($3.09 per share)
- FY 2024: Net income of $1.7B ($114.01 per share)
- R&D expenses decreased to $33.4M in Q4 2024 from $82.1M in Q4 2023
- G&A expenses increased to $16.7M in Q4 2024 from $7.8M in Q4 2023
Inhibrx Biosciences (NASDAQ: INBX) has released preliminary data from its Phase 1 trial of ozekibart (INBRX-109) combined with FOLFIRI for treating advanced colorectal cancer. The trial showed promising results among 10 evaluated patients, including one complete response, three partial responses, and six stable disease cases. The study demonstrated durable disease control lasting ≥180 days in 46.2% of patients, with a median progression-free survival of 7.85 months.
Treatment-emergent adverse events related to ozekibart were reported in 84.6% of patients, mostly grade 1 or 2 in severity, with grade ≥3 events in 30.8% of patients. Common side effects included nausea, increased alanine aminotransferase, diarrhea, and fatigue. Based on these encouraging results, Inhibrx has initiated an expansion cohort to enroll up to 50 patients, with data expected in Q3 2025.
Inhibrx Biosciences (Nasdaq: INBX) has secured a five-year term loan facility of up to $150 million through a loan and security agreement with Oxford Finance The company received an initial term loan of $100 million on January 13, 2025, with an additional $50 million available subject to lenders' discretion.
The agreement includes interest-only payments until March 2028. As part of the deal, Inhibrx issued warrants to purchase 140,741 shares of common stock at $14.21 per share, representing 2% of the initial term loan value. Additional warrants will be issued with any future funding.
The financing aims to provide strategic flexibility for Inhibrx's INBRX-109 and INBRX-106 programs, which are currently in clinical trials with data readouts expected later in 2025.
Inhibrx Biosciences (INBX) reported Q3 2024 financial results, showing a net loss of $43.9 million ($2.84 per share) compared to $51.8 million ($4.39 per share) in Q3 2023. The company held cash and equivalents of $196.3 million as of September 30, 2024, down from $226.9 million in June 2024. R&D expenses increased to $38.9 million from $38.1 million year-over-year, mainly due to expanded clinical trials. G&A expenses remained stable at $7.9 million. The company has two ongoing clinical programs with expected data readouts within 12 months.
Inhibrx (Nasdaq: INBX) has won a significant legal victory in a trade secrets case brought by I-Mab Biopharma in the United States District Court for the District of Delaware. The jury rejected all allegations of misappropriation that were filed on March 1, 2022, against Inhibrx and its Chief Scientific Officer, Brendan Eckelman, Ph.D. The lawsuit had claimed improper access and use of proprietary information during a prior arbitration proceeding where Dr. Eckelman served as an expert witness. The verdict validates Inhibrx's independent development processes and ethical conduct in advancing its therapeutic innovations.
Inhibrx Biosciences (Nasdaq: INBX) reported its Q2 2024 financial results and corporate highlights. Key points include:
1. Completion of separation from Former Parent on May 30, 2024
2. Cash and cash equivalents of $226.9 million as of June 30, 2024
3. R&D expenses increased to $67.6 million in Q2 2024
4. G&A expenses rose to $93.4 million in Q2 2024
5. Net income of $1.9 billion in Q2 2024, or $127.10 per share (basic)
The company now operates as a stand-alone entity focused on two clinical programs: ozekibart (INBRX-109) and INBRX-106.
Inhibrx announced that its stockholders have approved the sale of INBRX-101 to Sanofi. INBRX-101 is an augmentation therapy for alpha-1 antitrypsin deficiency (AATD). Before the sale, all non-101 assets and liabilities will be spun out into a new publicly traded company, New Inhibrx. Sanofi will acquire all outstanding shares of Inhibrx through a merger, offering $30 per share in cash and a contingent value right of $5 per share. Additionally, stockholders will receive one share of New Inhibrx for every four shares of Inhibrx common stock. Sanofi will also assume and retire Inhibrx's debt, and New Inhibrx will receive at least $200 million in cash. The transactions are expected to close soon, leading to Inhibrx's delisting from Nasdaq and cessation of SEC filings.
Inhibrx, Inc. announced an updated when-issued trading date for the anticipated spin-off of its subsidiary Inhibrx Biosciences, Inc. The spin-off will occur after the approval of the Company's acquisition by Sanofi at a special meeting on May 24, 2024. The trading of SpinCo common stock is expected to begin on a when-issued basis on May 28, 2024, under the symbol 'INXB.' The record date for the spin-off is May 17, 2024, with the distribution scheduled for May 29, 2024. The completion of the spin-off and merger is subject to closing conditions noted in the Company's Definitive Proxy Statement.
Inhibrx, Inc. has announced a record date set for May 17, 2024, for the distribution of 92% of shares of its subsidiary, Inhibrx Biosciences, Inc., to its common stockholders. The distribution is expected to occur on May 29, 2024, followed by the closing of the acquisition by Sanofi on May 30, 2024. Shareholders will receive one share of SpinCo common stock for every four shares of Inhibrx common stock held. Trading under the symbol 'INBX' will entitle shareholders to the distribution, with SpinCo common stock trading under 'INXB' until the completion of the distribution.